Zymeworks Inc.
Zymeworks Inc. (ZYME): 8 pipeline candidates · ~19 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
18.8 months
D/E 1.92 · 2% dilution
Lead: Approved
8 candidates
N/A
0 buys · 10 sells (180d)
A transparent, data-derived signal for Zymeworks Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.7B
Cash
$244.3M
Quarterly Burn
$45.7M
Runway
18.8 mo
Revenue
$2.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
212
Total value held
$1.14B
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 7,020,156 | $175.8M |
| blackrock, inc. | 4,553,888 | $114.0M |
| bvf inc/il | 3,734,142 | $93.5M |
| vanguard capital management llc | 3,411,160 | $85.4M |
| morgan stanley | 2,480,568 | $62.1M |
| bnp paribas asset management holding s.a. | 1,908,039 | $47.8M |
| citadel advisors llc | 1,250,518 | $31.3M |
| dimensional fund advisors lp | 1,139,135 | $28.5M |
| nextech invest, ltd. | 1,113,946 | $27.9M |
| state street corp | 1,011,777 | $25.3M |
Showing top 10 of 212 institutional holders of Zymeworks Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Zymeworks Inc.'s pipeline?
Zymeworks Inc. (ZYME) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Zymeworks Inc.'s lead drug candidate?
Zymeworks Inc.'s most advanced tracked candidate is pasritamig (Phase 3) for castration resistant prostate cancer.
What is Zymeworks Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Zymeworks Inc. has approximately 18.8 months of cash runway.
What is Zymeworks Inc.'s market capitalization?
Zymeworks Inc.'s market capitalization is approximately $1.7B.
Who is the CEO of Zymeworks Inc.?
Mr. Kenneth H. Galbraith C.A. is the chief executive officer of Zymeworks Inc. (ZYME).
Get the full picture on Zymeworks Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.